Design approach developed for bitopic kinase inhibitors targeting ABL1 and EGFR
Researchers enable development of bitopic inhibitors with enhanced activity against resistance mutations and reduced off-target toxicity.
Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
1 publisher has covered this in 1 article since 23 Sept 2026. Nature published first, on 23 September at 00:00 UTC.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- ABL1
- EGFR